Company profile
Decoy Therapeutics Inc.
NASDAQ: DCOY · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
31DFH 31DQ 40GM 9SS 39
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$12.5M
Employees
11
as of 2026-08-24
Market cap
$1.7M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$12.5M-$12.5M2025
Operating income-$12.6M-$12.6M2025
Total assets$11.1M$11.1M2025
Liabilities$5.2M$5.2M2025
Equity$5.9M$5.9M2025
Revenue trend
FY2018 – FY2022 · USD
FY18
FY18
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2020
By product
Grant, Castration-Resistant Prostate Study100%
By geography
Not disclosed.
The read
What is Decoy Therapeutics Inc.’s revenue?
Decoy Therapeutics Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Telo Genomics Corp.——Lobe Sciences Ltd.42DDakshidin Corporation31DProtagenic Therapeutics, Inc.——Welsis Corp.20DAzitra, Inc.29DNeighbors
Middlesex →Key facts
CEOFrederick E. Pierce
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: DCOY
Employees11
IPO date2015-01-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.